CO-VANTAGE-DATA-CENTERS
7.4.2020 15:02:06 CEST | Business Wire | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has signed a definitive agreement with InfraVia Capital Partners, along with the two founders of the business, to acquire Next Generation Data (NGD). Upon closing, Wales will mark Vantage’s sixth strategic market in Europe following its entrance into five markets (Berlin, Frankfurt, Milan, Warsaw and Zurich) announced in February 2020, including the acquisition of Etix Everywhere .
This acquisition will provide Vantage customers with access to Europe’s largest data center campus totaling 180MW, including an existing 72MW facility and 108MW of expansion capacity. The NGD campus is in the Cardiff Capital Region in South Wales, which includes the Welsh capital, and is the region’s economic hub.
Located on 50-acres, the existing NGD data center is a Tier III facility using 100% renewable energy. The facility is rich in connectivity and has fiber delivered by many Tier 1 service providers, offering customers low latency between Wales and London of less than 1.5 milliseconds. In addition, NGD Cloud Gateway provides multiple access services, including Express Route and Connect, and NGD recently became a new hosting facility for LINX Wales. The highly secure site meets the U.K. government’s highest standards, and is one of many reasons that multiple blue-chip, high growth companies currently house their IT infrastructure within NGD’s 750,000 square foot facility.
NGD’s CEO Justin Jenkins, an experienced technology and operations leader, will join Vantage as president, Vantage, U.K., once the acquisition closes. At NGD since its founding in 2007, Jenkins previously served as the company’s CTO and COO before being named CEO in 2018. He has also held leadership roles at Sony Computer Entertainment and several start-up technology companies.
“As the needs of our hyperscale, cloud and large enterprise customers continue to grow, Wales represents a highly attractive U.K. market offering both lower cost and greater scalability versus London,” said Sureel Choksi, president and CEO, Vantage Data Centers. “NGD customers benefit from very low network latency to London, low power costs and excellent fiber connectivity, coupled with the company’s massively scalable campus outside London’s highly constrained M25 area. We are thrilled to welcome Justin Jenkins and the entire NGD team to Vantage Europe.”
“The NGD team is excited to join Vantage Europe given our shared commitment to operational excellence, high quality facilities and sustainable building practices,” said Jenkins. “Vantage’s global footprint and broad customer relationships, combined with NGD’s growing hyperscale and enterprise U.K. customer base, position us ideally to accelerate the investment and growth of our U.K. business.”
The transaction will be funded with equity commitments from Digital Colony Partners and other investors in Vantage, as well as acquisition debt financing.
“The need for hyperscale data centers is more vital than ever, and we are thrilled to support Vantage Europe in its acquisition of NGD,” said Marc Ganzi, CEO of Digital Colony and CEO-elect of Colony Capital. “Despite the current market dislocation, Digital Colony remains committed to supporting its portfolio companies and meeting the ever-increasing needs of our valued customers around the globe. This strategic acquisition advances that goal, providing Vantage Europe with immediate scale and access to significant renewable energy in the important UK market.”
The transaction is subject to customary regulatory approvals and is expected to close in Q3 2020. Terms of the deal are not being disclosed.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across six markets in North America and five markets in Europe, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit www.vantage-dc.com
About NGD
Located in the Cardiff Capital Region, NGD is a purpose-built, carrier-neutral Tier III facility offering 750,000 square feet of highly secure and cost-effective space. NGD’s environmentally-friendly, high-level technology infrastructure is designed to meet and exceed the ever-increasing demand for more computing power. Among its many features are a high capacity 180 MVA power supply direct from the super grid and sourced from 100% renewable energy, as well as a variety of on-site, high-speed and low-latency carrier interconnects.
For more information, visit www.nextgenerationdata.co.uk
View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005497/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 12:00:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission
KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 12:00:00 CEST | Press release
KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
